Invention Grant
- Patent Title: Nerve growth factor mutant
-
Application No.: US16085977Application Date: 2017-03-17
-
Publication No.: US11213568B2Publication Date: 2022-01-04
- Inventor: Chao Wang , Lei Ma , Tianfei Du
- Applicant: Staidson (Beijing) Biopharmaceuticals Co., Ltd.
- Applicant Address: CN Beijing
- Assignee: Staidson (Beijing) Biopharmaceuticals Co., Ltd.
- Current Assignee: Staidson (Beijing) Biopharmaceuticals Co., Ltd.
- Current Assignee Address: CN Beijing
- Agency: Knobbe Martens Olson & Bear LLP
- Priority: CN201610159303.7 20160318
- International Application: PCT/CN2017/077038 WO 20170317
- International Announcement: WO2017/157326 WO 20170921
- Main IPC: C07K14/48
- IPC: C07K14/48 ; A61K38/18 ; C12N15/85 ; A61P25/00 ; A61K38/00
Abstract:
Provided is a nerve growth factor mutant, wherein same is an amino acid sequence as shown by any one of SEQ ID No: 3 to SEQ ID No: 21 in the sequence listing. The advantage of the nerve growth factor mutant lies in that the mutation of a nerve growth factor can alleviate side effects such as pain, falling within the field of biological pharmacy.
Public/Granted literature
- US20190105373A1 NERVE GROWTH FACTOR MUTANT Public/Granted day:2019-04-11
Information query
